Work

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

Year: 2017

Type: review

Source: Expert Opinion on Pharmacotherapy

DOI: 10.1080/14656566.2017.1299710

Authors: Megan C Turner, Kara Rossfeld, April K.S Salama, Douglas Tyler, Georgia Beasley

Institutions: Duke University, The Ohio State University, The University of Texas Medical Branch at Galveston

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2593411101

FWCI: 0.129

Cites: 84

Cited by: 8

Related to: 10